Stockscreener 앱 받기
264.34
0.29%
-0.78
Abbvie Inc 주식(ABBV)의 최신 뉴스
AbbVie Inc Lobbyists, 2025 - OpenSecrets
Comparative Analysis of AbbVie and Johnson & Johnson in a Shifting Market - Intellectia AI
AbbVie Says Botox Exempt From Medicare Price Negotiations - law360.com
US FDA approves AbbVie's drug for Parkinson's disease - Reuters
US FDA approves AbbVie’s drug for Parkinson’s disease - WTAQ
Investment Outlook Comparison: AbbVie vs. Pfizer - Intellectia AI
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026? - fool.com
ADARx Pharmaceuticals shares soar in Nasdaq debut after upsized IPO - Reuters
ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade - 24/7 Wall St.
Allergan Aesthetics - WCIV
ADARx Pharmaceuticals raises $446 million in upsized IPO - qz.com
Is AbbVie Inc. (ABBV) Rewriting the Bluechip Stocks Playbook? - Kalkine Media
AbbVie stock nears its record high after a quarterly beat - AD HOC NEWS
ADARx Pharmaceuticals Plans $350 Million IPO with AbbVie Investment - intellectia.ai
AbbVie stock heads into the open after a flat close - ad-hoc-news.de
RBC Capital Sticks to Its Buy Rating for AbbVie (ABBV) - The Globe and Mail
Reuters Momentum AI Austin Day 1: A New Way to Measure Whether AI Is Actually Paying Off - GlobeNewswire Inc.
AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026? - The Globe and Mail
AbbVie Stays Flat as 6,000-Property AI Hunts Better Molecules - Yahoo Finance
UChicago Medicine completes construction phase of AbbVie Foundation Cancer Pavilion, bringing new era of cancer care closer to reality - PR Newswire
AbbVie And Iambic Partner To Accelerate AI-Driven Drug Discovery In Immunology, Neuroscience And Oncology - Pulse 2.0
AbbVie | 9/24/26 - ktnv.com
Beyond Imbruvica: Can AbbVie Rebuild Its Oncology Portfolio? - The Globe and Mail
Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick? - Zacks Investment Research
What Is AbbVie (NYSE:ABBV) Adding to Healthcare AI Research? - Kalkine Media
AbbVie Says Health Canada Issues Notice of Compliance for EPKINLY in Follicular Lymphoma - Yahoo Finance
AbbVie stock heads into the open after a 0.02 percent gain - AD HOC NEWS
Prediction: Here's What $10,000 Invested in AbbVie Stock With Dividends Reinvested Could Be Worth in a Decade - Yahoo Finance
AbbVie: Revenue Pressure And Weakening Earnings Support A 'Sell' (NYSE:ABBV) - Seeking Alpha
AbbVie stock ends the day 0.2 percent higher at USD 266.45 - AD HOC NEWS
Nvidia Backed This AI Drug Startup. AbbVie Just Became a Partner Before Its IPO - Yahoo Finance
What Is AbbVie No Longer Telling You? - Trefis
2026 2H Healthcare Dividend Roundup: Johnson & Johnson Outshines AbbVie (NYSE:ABBV) - Seeking Alpha
AbbVie stock hits all-time high of 267.48 USD By Investing.com - Investing.com Nigeria
AbbVie stock hits all-time high of 267.48 USD - Investing.com
AbbVie (ABBV) Receives a Buy from Scotiabank - The Globe and Mail
AbbVie stock closes at USD 265.21 as EU approval adds support - AD HOC NEWS
Why is AbbVie (NYSE:ABBV) in focus amid today’s healthcare stocks discussion? - Kalkine Media
AbbVie (ABBV) Won EU Approval For RINVOQ In Pediatric Arthritis - Yahoo! Finance Canada
Where does AbbVie (NYSE:ABBV) go as medicine launches shifts? - Kalkine Media
AbbVie stock gains 0.3 percent ahead of the open - AD HOC NEWS
Pediatric Arthritis Treatments: AbbVie Expands RINVOQ to Children With Active pJIA - Trend Hunter
AbbVie (ABBV) Wins EU Approval for Rinvoq in Children. Why a Small Indication Still Matters - Yahoo Finance
AbbVie stock ends the day higher at USD 265.51 - AD HOC NEWS
AbbVie’s Rinvoq Wins 11th EU Approval in Pediatric Arthritis - AskTraders
AbbVie's Rinvoq Wins EU Approval in Juvenile Idiopathic Arthritis - Yahoo Finance
New EC approval for AbbVie’s Rinvoq - The Pharma Letter
Is AbbVie (NYSE:ABBV) Stock Worth Watching Today? - Kalkine Media
AbbVie receives EU approval for RINVOQ juvenile arthritis treatment - grafa.com
Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach - AbbVie News Center
AbbVie vs. Pfizer: Which is the Better Dividend Investment? - Intellectia AI
AbbVie Secures EU Approval for Rinvoq in Juvenile Arthritis - Yahoo Finance
AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September? - The Globe and Mail
ADARx sets $350 million IPO terms as AbbVie lines up a stake - The Pharma Letter
AbbVie’s Rinvoq gains EU approval for juvenile arthritis - Investing.com
European green light for AbbVie's Rinvoq pediatric expansion - marketscreener.com
AbbVie’s Rinvoq wins EU approval for pediatric arthritis - Investing.com
AbbVie Announces European Commission Approval of RINVOQ® for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis - Investing News Network
Key facts: AbbVie, Inc. $600M China outlay; House seeks trial files; 4.9% ADARx - TradingView
AbbVie Inc. stock rises 0.7 percent ahead of the open - AD HOC NEWS
AbbVie’s oral arthritis drug approved in EU for children as young as 2 - Stock Titan
Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV) - The Globe and Mail
AbbVie stock ends the day slightly higher at the close on Nasdaq - AD HOC NEWS
0.54%
자본화:
|
볼륨(24시간):